

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2007 (14.06.2007)

PCT

(10) International Publication Number
WO 2007/065215 A1

(51) International Patent Classification:

C07K 14/05 (2006.01) **A61K 39/245** (2006.01)
A61K 39/295 (2006.01) **C12N 15/09** (2006.01)
C12N 15/34 (2006.01)

(21) International Application Number:

PCT/AU2006/001854

(22) International Filing Date:

6 December 2006 (06.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2005906851 6 December 2005 (06.12.2005) AU

(71) Applicants (for all designated States except US): **THE AUSTRALIAN NATIONAL UNIVERSITY** [AU/AU]; Acton, ACT 0200 (AU). **QUEENSLAND INSTITUTE OF MEDICAL RESEARCH** [AU/AU]; Bramston Terrace, Herston, QLD 4006 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **THOMSON, Scott, Anthony** [AU/AU]; 98 McIntosh Circuit, Murrumbateman, NSW 2582 (AU). **DURAISWAMY, Jai, Kumar** [AU/AU]; Bramston Terrace, Herston, QLD 4006 (AU). **MOSS, Denis, James** [AU/AU]; 29 Mitchell Street, Arana Hills, QLD 4054 (AU).

(74) Agent: **SPRUSON & FERGUSON**; GPO Box 3898, Sydney, NSW 2001 (AU).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES

NPC SAVINE Construction



(57) Abstract: The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship relative to their linkage in the at least one parent EBV polypeptide.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.